Structure Therapeutics, Inc.NASDAQ: GPCR

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

· Issued by Structure Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Structure Therapeutics Inc., which develops oral small-molecule drugs for metabolic diseases with a focus on chronic weight management, will present two posters on its investigational obesity drug aleniglipron at ObesityWeek, The Obesity Society's Annual Meeting, taking place November 14–17, 2026 in National Harbor, Maryland.

Key details

  • Both posters are scheduled for November 15, 2026, 2:30 p.m. – 3:30 p.m. ET in Exhibit Hall BCD.
  • One poster covers the open-label extension (a follow-on phase where participants know they are receiving the drug) of the ACCESS trial of aleniglipron in people living with overweight or obesity.
  • The other poster covers dose-ranging effects (results at different doses) of aleniglipron from the ACCESS trials.
  • Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule designed to activate the GLP-1 (glucagon-like peptide-1) receptor, which Structure Therapeutics describes as a clinically validated target for the treatment of obesity and type 2 diabetes mellitus.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweekr-2026

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD.

Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension
Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET
Location: Exhibit Hall BCD

Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials
Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET
Location: Exhibit Hall BCD

About Aleniglipron
Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Jen Robinson
Structure Therapeutics Inc.
Jennifer.Robinson@structuretx.com

Media:
Dan Budwick
1AB
Dan@1abmedia.com


View original source (GlobeNewswire)Structure Therapeutics, Inc. on 6ix